The board of directors of Biovitrum utilizes authorization to
repurchase shares to secure the compan
(Thomson Reuters ONE) - The Annual General Meeting of Biovitrum resolved on 28 April 2009 toissue 231,585 series C shares to secure that the company can fulfillits commitment according to the performance based, long-term shareprogram for 2009 ("Share Program 2009"). Furthermore, the AnnualGeneral Meeting resolved to authorize the board of directors torepurchase all issued series C shares for a price per sharecorresponding to the quota value of the Biovitrum share, i.e. intotal SEK 127,069.9623. The series C shares will thereafter beconverted to common shares in the number that is required to securedelivery under the Share Program 2009.The board of directors of Biovitrum has resolved to utilize theauthorization for this purpose and to immediately repurchase allissued series C shares in accordance with the resolution by theAnnual General Meeting on 28 April 2009. Biovitrum currently holds284,000 own series C shares which were issued during 2008.For further information, please contact:Biovitrum AB (publ)Martin Nicklasson, CEOPhone: +46 8 697 20 00Göran Arvidson, CFOPhone: +46 70 633 30 42Erik Kinnman, VP Investor RelationsPhone: +46 73 422 15 40erik.kinnman(at)biovitrum.comAbout BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. Biovitrum has revenues of approximately SEK 1.2billion and approximately 400 employees (prior to the Transaction).Biovitrum's head office is located in Sweden and the share is listedon the NASDAQ OMX Stockholm. For more information please visitwww.biovitrum.com.The above information has been made public in accordance with theSecurities Market Act and/or the Financial Instruments Trading Act.The information was published at 8:30 CET on December 3, 2009.http://hugin.info/134557/R/1358876/331024.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 03.12.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 9195
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 442 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The board of directors of Biovitrum utilizes authorization to
repurchase shares to secure the compan"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
